A systematic review and meta-analysis on the therapeutic equivalence of statins

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 2, 2010, Pages 139-151

  Weng, T C ^a   Yang, Y H Kao ^a   Lin, S J ^b   Tai, S H ^c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Statins; Systematic review; Therapeutic equivalence

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIBLIOGRAPHIC DATABASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MEDLINE; META ANALYSIS; MONOTHERAPY; MYALGIA; MYOPATHY; OUTCOME ASSESSMENT; REVIEW; RHABDOMYOLYSIS; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTIC EQUIVALENCY;

EID: 77749248851     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01085.x     Document Type: Review

References (20)

1. Grundy SM, Cleeman JI, Merz CN et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110, 227 239.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults final report. Circulation, 106, 3143 3421.
3. Chong PH (2002) Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Annals of Pharmacotherapy, 36, 1907 1917.
4. Zhou Z, Rahme E, Pilote L (2006) Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention American Heart Journal, 151, 273 281.
5. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. British Medical Journal, 326, 1423 1429.
6. Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitors (Statins). VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. Available at: http://www.pbm.va.gov/reviews/HMGStatins04-09-03.pdf (accessed 24 December 2006).
7. Oregon Health Resources Commission HMG-CoA Reductase Inhibitors (Statins) Subcommittee Report, 3 edn. Oregon Health Resources Commission. Available at: http://egov.oregon.gov/DAS/OHPPR/ORRX/HRC/evidence-based-reports.shtml (accessed 24 December 2006).
8. Cochrane Handbook for Systematic Reviews of Interventions 4·2·5 Available at: http://www.cochrane.org/resources/handbook/ hbook.htm (accessed 24 December 2006).
9. Undertaking Systematic Reviews of Research on Effectiveness Center for Review and Dissemination. Available at: http://www.york.ac.uk/inst/crd/report4. htm (accessed 24 December 2006).
10. Harris RP, Helfand M, Woolf SH et al. (2001) Current methods of the US preventive services task force: a review of the process. American Journal of Preventive Medicine, 20 (Suppl. 21 35.
11. Thompson PD, Clarkson PM, Rosenson RS (2006) An assessment of statin safety by muscle experts. American Journal of Cardiology, 97, 69C 76C.
12. Cannon CP, Braunwald E, McCabe CH et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350, 1495 1504.
13. Pedersen TR, Faergeman O, Kastelein JJP et al. (2005) High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA: The Journal of the American Medical Association, 294, 2437 2445.
14. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). American Journal of Cardiology, 81, 582 587. (Pubitemid 28182422)
15. Jones PH, Davidson MH, Stein EA et al. (2003) Comparison of the efficacy and safety of rosuvastatin vs. atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). American Journal of Cardiology, 92, 152 160.
16. Zhou Z, Rahme E, Abrahamowicz M et al. (2005) Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ: Canadian Medical Association Journal, 172, 1187 1194.
17. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR (2006) Statin-related adverse events: a meta-analysis. Clinical Therapeutics, 28, 26 35.
18. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH (2005) The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation, 111, 3051 3057.
19. Davidson MH, Clark JA, Glass LM, Kanumalla A (2006) Statin safety: an appraisal from the adverse event reporting system. American Journal of Cardiology, 97, 32C 43C.
20. Jacobson TA (2006) Statin safety: lessons from new drug applications for marketed statins. American Journal of Cardiology, 97, 44C 51C.